What is Pegfilgrastim Biosimilar Market?
Pegfilgrastim is a long-acting version of filgrastim (Neupogen) that is indicated for selected cancer patients who are undergoing chemotherapy to increase the production of anti-infection white blood cells. The indication is specific to those receiving myelosuppressive anticancer drugs that are associated with a clinically significant incidence of febrile neutropenia. The market for pegfilgrastim biosimilars consists of the sale of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment to reduce the risk of infection for patients undergoing immunosuppressive treatments such as chemotherapy. The drug has other uses that involve protecting against infections where the immune system is weakened, such as bone marrow transplants. Biosimilars are biological products that are manufactured in such a way that they are identical to an already approved biological called the reference medicine. Biosimilars should demonstrate similar safety and efficacy compared to the reference biological product. Pegfilgrastim is a PEGylated form of the filgrastim analog of recombinant human granulocyte colony-stimulating factor (G-CSF).
The market study is being classified by Type (Ristempa, Tezmota, Fulphila, Pelgraz and Udenyca), by Application (Chemotherapy Induced Neutropenia, Transplantation and Others) and major geographies with country level break-up.
Coherus Biosciences Inc. (United States), Biocon (India), Mylan (United States), Pfizer (United States), Sandoz (Novartis) (Germany), USV Biologics (India), Apotex Pty Ltd (Australia), Stada Arzneimittel (Germany), Kyowa Kirin Co., Ltd. (Japan), Qilu Pharmaceutical (China) and Gennova Biopharmaceuticals Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lupin Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Fresenius Kabi (Germany) and Napp Pharmaceuticals (United Kingdom).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Pegfilgrastim Biosimilar market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Pegfilgrastim Biosimilar market by Type, Application and Region.
On the basis of geography, the market of Pegfilgrastim Biosimilar has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- An Increased Prevalence of Cancer
- Low Costs of Biosimilars
- Increased Adoption of the Biosimilars
- Increase In Healthcare Access and Rising Prevalence of Chronic Diseases
- Revised FDA Regulations to Facilitate Biosimilar Drug Development
- Stringent Regulations Related To Biosimilar Approvals and Prolonged Production
- Increase in Healthcare Expenditure
- Increase in Pharmaceutical R&D Expenditure
- Side Effects associated With the Drugs
In October 2018, Sandoz, which is a Novartis biosimilars division, had received FDA approval for its biosimilar HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis as well as juvenile idiopathic arthritis in patients four years and older.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Providers of Pegfilgrastim Biosimilar, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase